REGN SignalReason for this trade
1: Market is taking pullback from trendline
2: market is near high supply area
Next report date
Report period
Q2 2024
EPS estimate
10.23EUR
Revenue estimate
3.18 BEUR
33.6EUR
3.58 BEUR
11.88 BEUR
105.50 M
About Regeneron Pharmaceuticals, Inc.
Sector
CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Website
Employees (FY)
13.45 K
Founded
1988
FIGI
BBG000HCZ2Q3
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where RGO is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange REGENERON PHARMACEUTICALS INC. stocks are traded under the ticker RGO.
REGENERON PHARMACEUTICALS INC. is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
RGO earnings for the last quarter are 10.75 EUR per share, whereas the estimation was 9.72 EUR resulting in a 10.52% surprise. The estimated earnings for the next quarter are 9.43 EUR per share. See more details about REGENERON PHARMACEUTICALS INC. earnings.
REGENERON PHARMACEUTICALS INC. revenue for the last quarter amounts to 3.11 B EUR despite the estimated figure of 2.98 B EUR. In the next quarter revenue is expected to reach 2.99 B EUR.
Yes, you can track REGENERON PHARMACEUTICALS INC. financials in yearly and quarterly reports right on TradingView.
RGO net income for the last quarter is 1.05 B EUR, while the quarter before that showed 953.37 M EUR of net income which accounts for 10.20% change. Track more REGENERON PHARMACEUTICALS INC. financial stats to get the full picture.
No, RGO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RGO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REGENERON PHARMACEUTICALS INC. stock right from TradingView charts — choose your broker and connect to your account.
As of May 2, 2024, the company has 13.45 K employees. See our rating of the largest employees — is REGENERON PHARMACEUTICALS INC. on this list?
We've gathered analysts' opinions on REGENERON PHARMACEUTICALS INC. future price: according to them, RGO price has a max estimate of 1111.40 EUR and a min estimate of 673.01 EUR. Watch RGO chart and read a more detailed REGENERON PHARMACEUTICALS INC. stock forecast: see what analysts think of REGENERON PHARMACEUTICALS INC. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REGENERON PHARMACEUTICALS INC. EBITDA is 4.26 B EUR, and current EBITDA margin is 36.36%. See more stats in REGENERON PHARMACEUTICALS INC. financial statements.